Novo Nordisk
236,90 DKK
+2,60 %
1.013 følger denne virksomhed
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Værdiansættelse
Resultatopgørelse
Kvartalsdata
Resultatopgørelse
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Novo Nordisk
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Omsætning | 122.021,0 | 126.946,0 | 140.800,0 | 176.954,0 | 232.261,0 | 290.403,0 | 309.064,0 |
| vækst-% | 4,0 % | 10,9 % | 25,7 % | 31,3 % | 25,0 % | 6,4 % | |
| EBITDA | 58.144,0 | 59.879,0 | 64.669,0 | 82.171,0 | 111.987,0 | 147.446,0 | 149.640,0 |
| EBIT | 52.483,0 | 54.126,0 | 58.644,0 | 74.809,0 | 102.574,0 | 128.339,0 | 127.658,0 |
| Overskud før skat | 48.553,0 | 53.130,0 | 59.080,0 | 69.062,0 | 104.674,0 | 127.191,0 | 130.540,0 |
| Netto indkomst | 38.951,0 | 42.138,0 | 47.757,0 | 55.525,0 | 83.683,0 | 100.988,0 | 102.434,0 |
| EPS | 8,20 | 9,03 | 10,39 | 12,26 | 18,67 | 22,67 | 23,06 |
| Udbytte | 4,18 | 4,55 | 5,20 | 6,20 | 9,40 | 11,40 | 11,70 |
| Udbytte ratio | 50,9 % | 50,4 % | 50,0 % | 50,6 % | 50,3 % | 50,3 % | 50,7 % |
Lønsomhed og afkast på kapital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 47,7 % | 47,2 % | 45,9 % | 46,4 % | 48,2 % | 50,8 % | 48,4 % |
| EBIT-% | 43,0 % | 42,6 % | 41,7 % | 42,3 % | 44,2 % | 44,2 % | 41,3 % |
| ROE | 67,6 % | 66,5 % | 67,5 % | 66,5 % | 78,5 % | 70,4 % | 52,8 % |
| ROI | 31,0 % | 29,1 % | 24,6 % | 23,0 % | 26,6 % | 21,7 % | 18,9 % |